AndroGel $448M Pay-For-Delay Disgorgement Spiked On Appeal, But Some Of FTC Complaint Resurrected
Executive Summary
AbbVie and FTC both see wins and setbacks in Third Circuit ruling on case involving reverse-payment patent settlement with Teva.
You may also be interested in...
FTC Argues Forest Side Deals In Bystolic Pay-For-Delay Case May Be Unjustified Payments
Commission backs purchasers and end payers in appeal of district court dismissal of suits against Forest and six generic manufacturers. It contends the court contravened Supreme Court’s Actavis decision and proffered its own justifications for side deals in patent settlements.
FTC Argues Forest Side Deals In Bystolic Pay-For-Delay Case May Be Unjustified Payments
Commission backs purchasers and end payers in appeal of district court dismissal of suits against Forest and six generic manufacturers. It contends the court contravened Supreme Court’s Actavis decision and proffered its own justifications for side deals in patent settlements.
FTC Navigating Regulatory Restraints As Bill To Restore Monetary Relief Authority Faces Challenges
Congressional Republicans and biopharma stakeholders support legislation clarifying the Federal Trade Commission’s authority to assess monetary penalties but argue the House legislation needs guardrails.